期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

替米沙坦对老年不稳定型心绞痛患者血清hs-CRP、MMP-9和AngⅡ水平的影响 被引量：2

暂未订购
导出
摘要 目的探讨血管紧张素Ⅱ受体阻断剂(ARB)类药物替米沙坦对老年不稳定型心绞痛患者血清高敏C-反应蛋白(hs-CRP)、基质金属蛋白酶-9(MMP-9)和血管紧张素Ⅱ(AngⅡ)的影响。方法用随机方法(分层抽样法)将100例老年不稳定型心绞痛患者分为常规治疗组(50例)和替米沙坦组(50例)。测定治疗前和治疗后6个月血清hs-CRP、MMP-9和AngⅡ水平,并随访心血管事件的发生。结果常规治疗组和替米沙坦组hs-CRP、MMP-9及AngⅡ的水平在治疗前比较差异无统计学意义,分别为(12.65±2.84)ng/mL、(113.27±24.15)ng/mL、(401.81±335.85)pg/mL及(12.97±2.46)ng/mL、(119.62±47.82)ng/mL、(407.73±354.51)pg/mL(P>0.05)。常规治疗组和替米沙坦组hs-CRP、MMP-9的水平在治疗6个月后均明显降低,但替米沙坦组较常规治疗组更低,分别为(8.84±8.17)ng/mL、(51.84±22.34)ng/mL及(7.58±8.71)ng/mL、(38.14±23.47)ng/mL,组间比较有统计学意义(P<0.05);两组血清AngⅡ的水平在治疗6个月后均有所升高(P>0.05)。结论与常规治疗相比,加用替米沙坦后能够明显降低老年不稳定型心绞痛患者血清hs-CRP和MMP-9的水平,并有改善老年不稳定型心绞痛患者预后的趋势。
作者 郭倩云 郭完计 李晶 来春林
机构地区 山西医科大学第一临床医学院 山西省晋城市人民医院 山西省人民医院
出处 《中西医结合心脑血管病杂志》 2012年第7期775-777,共3页 Chinese Journal of Integrative Medicine on Cardio-Cerebrovascular Disease
基金 山西省科技攻关基金项目(No.20080311073)
关键词 替米沙坦 不稳定型心绞痛 C-反应蛋白 基质金属蛋白酶-9 血管紧张素Ⅱ
分类号 R541.4 [医药卫生—心血管疾病] R256.2 [医药卫生—中医内科学]
  • 相关文献

参考文献12

  • 1Andrie RP, Bauriedel G, Braun P,et al. Increased expression of C-reactive protein and tissue faclor in aculc coronary syndrome, lesions correlation with serum C rc, acliw protein, angioscopic findings, and modification by statins[J]. Aherosclerosis, 2009, 202(1):22.
  • 2郭完计,来春林.脂蛋白(a)及高敏C-反应蛋白与冠状动脉狭窄病变的相关研究[J].中国心血管病研究,2008,6(9):643-646. 被引量：7
  • 3Dahlof B, Devereux RB, Kjeldsen SE,et al. Cardiovascular morbidi- ty and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE) :A randomised trial against atenolol [J]. Lancet,2002,359(9311) =995 - 1003.
  • 4郑虹,米树华,杨红霞,赵怡,陶红,李敏,关杨.替米沙坦对老年原发性高血压伴代谢综合征血尿酸和超敏C反应蛋白的影响[J].心肺血管病杂志,2011,30(2):107-110. 被引量：19
  • 5陈韵岱.冠状动脉易损斑块的识别[J].心肺血管病杂志,2010,29(S1):7-9. 被引量：6
  • 6Smith DH. Comparison of angiotensin II type 1 receptor antago nists in the treatment of essential hypertension[J] Drugs, 2008, 68(9) :1207 - 1225.
  • 7Doggrell SA. Telmisartan - killing two birds with one stone[J]. Expert Opin Pharmacother,2004,5(11) =2397 - 2400.
  • 8Battershill AJ,Scott IJ. Telmisatrtan:A review of its use in the management of hypertension[J]. Drugs, 2006,66 (1) = 51 - 83.
  • 9Yamagishi S,Takeuchi M. Telmisartan is a promising cardio meta-bolic sartan due to its unique PPAR - gamma - inducing property [J]. Med Hypotheses,2005,64(3) =476 - 478.
  • 10Kurtz TW,Pravenec M. Antidiabetic mechanisms of angiotensin converting enzyme inhibitors and angiotensin I receptor antago- nists= Beyond the renin- angiotensin system [J]. H ypertens, 2004,22(12) 2253 - 2261.

二级参考文献46

  • 1刘静,赵冬,王薇,刘军,孙佳艺,吴兆苏.北京自然人群代谢综合征发病率及影响因素的研究[J].心肺血管病杂志,2007,26(2):65-68. 被引量：14
  • 2[1]Scano AM,Nakajima K,Edelstein C.Apoprotein(a) structure and biology.Front Biesei,2002,6:546-554.
  • 3[2]Yu H,Rifai N.High sensitivity C-reactive protein and atheroscleroais:from theory to theray.Clin Bioehem,2000,33:601-610.
  • 4[3]Romn PA,Green CE,Reagan K,et al.Relation of serum lipoprotein(a) cholesterol levels to presence and severity of angiography coronary artery disease.Am J Cardiol,1991,67:479-483.
  • 5[4]Wang XL,Tam C,Mc Credie RM,et al.Determinants of severity of coronary artery disease in Australian men and women.Circulation,1994,89:1974-1981.
  • 6[5]Bndde T,Fechtrup C,Bosenberg E,et al.Plasma Lp (a) levels correlate with number,severity and legth-extension of coronary lesion in patients undergoing coronary arteriograhy for clinic-ally suspected coronary atherosclerosis.Athereseler Thromb,1994,14:1730-1736.
  • 7[6]Peynet J,Beandeux JL,Woimant F,et al.Apolipoprotein (a) size polymorphism in young adults witch is chemic stroke.Atheroaclerosis,1999,142:233-239.
  • 8[7]Nguyen TT,Ellefson RD,Hedge DO,et al.Predictive value of elestrophoretical detested lipoprotein (a) for coronary heart disease and cerebrovaacular disease in a community based cohort of 9936 men and women.Circulation,1997,96:1390-1397.
  • 9[9]Inore S,Egashira K,Ni W,et al.Anti-monesyte ehemoatrantant protein-1 gene therapy limits progression and destabilization of established atheroaclerosis in apolipoproteinE-Knockort mice.Circulation,2002,106:2700-2706.
  • 10[10]Pearson TA,Mensah GA.Markers of inflammation and cardiovascular disease.Circulation,2003,107:499-511.

共引文献34

同被引文献39

  • 1于海波,韩雅玲,王祖禄,张新娅,佟铭,许凤芝.替米沙坦降压疗效的临床研究[J].高血压杂志,2004,12(6):515-518. 被引量：21
  • 2林泽鹏,金光临,张志伟.替米沙坦对老年高血压不稳定性心绞痛患者脂联素及C反应蛋白的影响[J].中华老年医学杂志,2005,24(8):631-633. 被引量：11
  • 3Geft D, Schwartzenberg S, GeorgeJ, et al. Circulating endothelial progenitor cells in cardiovascular disorders[J]. Expert Rev Cardiovasc Ther,2008,6(9): 1115-112l.
  • 4Mills NL, Tura 0, Padfield GJ ,et al. Dissociation of phenotypic and functional endothelial progenitor cells in patients undergoing percutaneous coronary intervention[J]' Heart, 2009,95(14):2003-2008.
  • 5Istrosch F, Herbrig K, Oelschlaegei U, et al. PPAR-y agonist rosiglitazone increases number and migratory activity of cultured endothelial progenitor cells[J]. Atherosclerosis, 2005, 183(1): 163-167.
  • 6Yamagishi S, Takeuchi M. Telmisartan is a promising cardio metabolic sartan due to its unique PPAR-gamma-inducing property[J]. Med Hypotheses, 2005,64(3) : 476-478.
  • 7Kurtz TW, Pravenec M. Antidiabetic mechanisms of angiotensin converting enzyme inhibitors and angiotensin IT receptor antagonists: beyond the rennin-angiotensin system[J]. Hypertens , 2004,22(12) : 2253-226l.
  • 8Zamptaki A. Vascular repair by endothelial progenitor cells[J]. Cardiovasc Res,2008,78(3) :413-42l.
  • 9Doggrell SA. Telmisartan-killing two birds with one stonel]]. Expert Opin Pharmacother , 2004,5(11) : 2397-2400.
  • 10Yang N. Apolipoprotein A-I mimetic peptide reverse D-4F improves the biological functions of mouse bone marrow?derived late EPCs via PI3K/ AKT / eNOS pathway[J]. Mol Cell Biochem,2013,377(1/2) :229-236.
中西医结合心脑血管病杂志
2012年 第7期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部